About
Contact & Profiles
A5055524047
Research Areas
- Synthesis and biological activity
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
German University in Cairo
2022
Anticancer drug conjugates may benefit from simultaneous action at two targets potentially overcoming the drawbacks of current cancer treatment, such as insufficient efficacy, high toxicity, and development resistance. Compared to a combination single-target drugs, they offer an advantage pharmacokinetic simplicity fewer drug-drug interactions. Here, we report series compounds connecting tamoxifen or endoxifen with EGFR-inhibitor gefitinib via covalent linkage. These hybrid ligands retain...
10.1021/acs.jmedchem.1c01646
article
EN
Journal of Medicinal Chemistry
2022-03-14
Coming Soon ...